IGM Biosciences, developing IgM antibodies for various diseases, sees Q1 2023 cash decrease, but collaboration revenues rise. Imvotamab trial results disappoint; focus shifts to combination therapies, ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...

IGM Biosciences is developing antibodies that are different from most monoclonal antibodies currently in use. They have two main pipeline projects focused on cancer and rheumatologic disease. The ...

Sanofi will pay IGM Biosciences $150 million and potentially billions more in milestone payments as part of a deal to develop agonist antibodies for cancer and inflammatory diseases. The well-known ...

Zika virus (ZIKV) infection is a potentially teratogenic illness, causing up to one in seven infants born to infected mothers to suffer neurodevelopmental deficits. A new study published in the ...